CoChat

Genome-scale in vivo CRISPR screen identifies RNLS as a target for beta cell protection in type 1 diabetes

Open access
Cai, Erica P., Ishikawa, Yuki, Zhang, Wei, Leite, Nayara C., Li, Jian, Hou, Shurong, Kiaf, Badr, Hollister-Lock, Jennifer, Yilmaz, Nese Kurt, Schiffer, Celia A., Melton, Douglas A., Kissler, Stephan, Yi, Peng · 2020 · Nature Metabolism
Cited by 100

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Abstract

Type 1 diabetes (T1D) is caused by the autoimmune destruction of pancreatic beta cells. Pluripotent stem cells can now be differentiated into beta cells, thus raising the prospect of a cell replacement therapy for T1D. However, autoimmunity would rapidly destroy newly transplanted beta cells. Using a genome-scale CRISPR screen in a mouse model for T1D, we show that deleting RNLS, a genome-wide association study candidate gene for T1D, made beta cells resistant to autoimmune killing. Structure-based modelling identified the U.S. Food and Drug Administration–approved drug pargyline as a potential RNLS inhibitor. Oral pargyline treatment protected transplanted beta cells in diabetic mice, thus leading to disease reversal. Furthermore, pargyline prevented or delayed diabetes onset in several mouse models for T1D. Our results identify RNLS as a modifier of beta cell vulnerability and as a potential therapeutic target to avert beta cell loss in T1D. Pluripotent stem cell–derived beta cells to treat type 1 diabetes are vulnerable to autoimmune destruction following transplantation. Using an in vivo CRISPR screen, Cai et al. identify RNLS as a modifier of beta cell vulnerability to autoimmune destruction.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s42255-020-0254-1

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Cited by

See all 100

Metadata

Authors
Cai, E. P., Ishikawa, Y., Zhang, W., Leite, N. C., Li, J., Hou, S., Kiaf, B., Hollister-Lock, J., Yilmaz, N. K., Schiffer, C. A., Melton, D. A., Kissler, S., & Yi, P.
Venue
Nature Metabolism
Published
2020-07-27
Volume
2
Issue
9
Pages
934-945
ISSN
2522-5812 (ISSN-L)
OpenAlex
W3045045289
Cited by
100
References
13
FWCI
6.80
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Genome-scale in vivo CRISPR screen identifies RNLS as a target for beta cell protection in type 1 diabetes. https://app.cochat.ai/papers/10.1038/s42255-020-0254-1
The paper
Cai, E. P., Ishikawa, Y., Zhang, W., Leite, N. C., Li, J., Hou, S., Kiaf, B., Hollister-Lock, J., Yilmaz, N. K., Schiffer, C. A., Melton, D. A., Kissler, S., & Yi, P. (2020). Genome-scale in vivo CRISPR screen identifies RNLS as a target for beta cell protection in type 1 diabetes. Nature Metabolism. https://doi.org/10.1038/s42255-020-0254-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.